Immatics N.V. (IMTX) vs MannKind Corporation (MNKD)

Immatics N.V. and MannKind Corporation are both Biotechnology companies. Immatics N.V. and MannKind Corporation are of similar size ($1.1B and $1.0B). MannKind Corporation grew revenue faster over the last twelve months: 30.5% against −65.0%. MannKind Corporation has the higher net margin (−11.1% vs −489.4%) and the higher return on invested capital (2.36% vs −84.8%). Across the 17 metrics below, MannKind Corporation leads on 14 and Immatics N.V. on 3.

Valuation

Metric IMTX MNKD Biotechnology median
P/E n/m n/m 8.50
P/S 18.67 2.39 9.71
P/B 1.98 n/m 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m 39.75 0.64
EV/Sales 13.18 3.18 9.21
Earnings yield (27.68%) (4.28%) (33.15%)
Free cash flow yield (26.17%) (1.93%) (25.50%)

Profitability

Metric IMTX MNKD Biotechnology median
Gross margin 100.00% 75.39% 65.16%
Operating margin (536.26%) 2.34% 0.00%
Net margin (489.35%) (11.08%) 0.00%
Free cash flow margin (488.01%) (4.61%) 0.00%
Return on equity (48.53%) 71.36% (56.36%)
Return on assets (39.83%) (7.62%) (48.04%)
Return on invested capital (84.83%) 2.36% 0.00%

Growth

Metric IMTX MNKD Biotechnology median
Revenue growth (TTM) (64.99%) 30.46% 6.02%
EPS growth (last fiscal year) (1,313.33%) (80.00%) 30.26%
Revenue growth, 5-year CAGR 11.81% 39.89% 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric IMTX MNKD Biotechnology median
Debt to equity 0.00 (6.28) 0.00
Current ratio 7.54 1.72 4.72
Net debt to EBITDA 2.04 5.32 0.96

Dividend

Metric IMTX MNKD Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric IMTX MNKD Biotechnology median
Market cap 1.07b 1.03b 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack